Zura Bio (NASDAQ:ZURA) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $15.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.75.

Zura Bio Stock Down 0.2 %

Shares of ZURA stock opened at $4.37 on Monday. The firm’s 50-day moving average is $4.16 and its two-hundred day moving average is $4.08. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities analysts predict that Zura Bio will post -0.47 EPS for the current fiscal year.

Insider Activity

In other news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Great Point Partners LLC raised its position in Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after buying an additional 1,884,501 shares during the last quarter. Armistice Capital LLC raised its position in Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $8,446,000. Affinity Asset Advisors LLC purchased a new position in shares of Zura Bio in the 1st quarter valued at about $1,157,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares in the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.